公开(公告)号：US10821100B2

公开(公告)日：2020-11-03

申请号：US16423992

申请日：2019-05-28

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: A61K31/4196 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D417/10 ,  C07D417/12 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D413/12 ,  A61K31/422

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US20190282548A1

公开(公告)日：2019-09-19

申请号：US16423992

申请日：2019-05-28

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: A61K31/4196 ,  A61K31/4245 ,  C07D401/10 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/428 ,  A61K31/433 ,  A61K31/422 ,  C07D249/12 ,  C07D417/10 ,  C07D405/12 ,  C07D403/12 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D409/14 ,  C07D417/12 ,  C07D413/10 ,  C07D413/12

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US20180200229A1

公开(公告)日：2018-07-19

申请号：US15919460

申请日：2018-03-13

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: A61K31/4196 ,  A61K31/4245 ,  C07D401/10 ,  C07D413/12 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/428 ,  A61K31/433 ,  A61K31/422 ,  C07D249/12 ,  C07D417/10 ,  C07D405/12 ,  C07D403/12 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D409/14 ,  C07D417/12 ,  C07D413/10

CPC classification number: A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US20160339000A1

公开(公告)日：2016-11-24

申请号：US15228681

申请日：2016-08-04

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: A61K31/4196 ,  A61K31/5377 ,  A61K31/422 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/4245

CPC classification number: A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US10391083B2

公开(公告)日：2019-08-27

申请号：US15919460

申请日：2018-03-13

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: C07D249/12 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  A61K31/422

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US09949955B2

公开(公告)日：2018-04-24

申请号：US15228681

申请日：2016-08-04

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: A61K31/4196 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  A61K31/422

CPC classification number: A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

公开(公告)号：US09439890B2

公开(公告)日：2016-09-13

申请号：US14745204

申请日：2015-06-19

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Laxmikant A. Gharat ,  Nagarajan Muthukaman ,  Neelima Khairatkar-Joshi ,  Vidya G. Kattige

IPC: C07D249/08 ,  A61K31/4196 ,  A61K31/428 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12

CPC classification number: A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/5377 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12

Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.